Ceci Zak, Sanofi-Aventis US
The catalyst for innovation in the current environment is that people are living longer and the industry is not equipped to handle the significant burden that will place on the system.
Ceci Zak
Vice President, General Therapeutics Marketing, Sanofi-Aventis US
The catalyst for innovation in the current environment is that people are living longer and the industry is not equipped to handle the significant burden that will place on the system. This begs the question of how we can meet the future needs of the healthcare system—and how we can pay for it. We need to engage in the disruptive innovation that is critical to meet the evolving needs of the elderly.
In 10 years, I think the traditional pharma/bio model will have evolved from a treatment approach to one of providing total healthcare solutions, including preventative and diagnostic products, treatments, and maintenance support for patients. Thus, there will be a shift from our current target audiences (typically physicians) to the entire continuum of healthcare treaters.
I see my current roles as a senior-level businesswoman at Sanofi-Aventis and the president of the Healthcare Businesswomen's Association (HBA) as my great accomplishments. My role at HBA allows me to lead a board of directors that oversees numerous complex and successful events, such as WOTY (Woman of the Year), the Annual Leadership Conference, and other educational offerings provided by 14 chapters worldwide. During my presidential tenure at HBA, we are shoring up the strategic growth platform that will sustain the long-term viability of the organization. It's a wonderful way to give back!
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
